Intellectual Property - November 12, 2016
InDex Pharmaceuticals gets new patent granted in the US
InDex Pharmaceuticals Holding has announced that a new method of use patent for the drug candidate cobitolimod will be granted by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding […]
Financing - September 22, 2016
InDex Pharmaceuticals raises 250 million SEK
The Stockholm based company InDex Pharmaceuticals announces new issue of shares of SEK 250 million. The issue also includes an overallotment option of 25 million. The subscription period runs until September 27, 2016. InDex main owners SEB Venture Capital, Industrifonden and NeoMed Management has made significant subscription commitments in the issue of new shares, which through […]
Acquisition - July 1, 2015
InDex, Almirall S.A End Agreement
InDex Pharmaceuticals terminated a license agreement with Almirall S.A. involving the drug candidate Kappaproct® for the treatment of ulcerative colitis. The agreement had given Almirall licensed exclusive rights to Kappaproct® for the European market. Now InDex regains all worldwide development and commercialization rights for Kappaproct®, which is in late-stage clinical development. “With global rights to […]
In a new job - February 12, 2015
InDex Appoints New CEO
Peter Zerhouni has been named the new CEO of InDex Pharmaceuticals and is scheduled to take office April 1. He will succeed Jesper Wiklund, who has led the company since 2011. Wiklund has decided to leave InDex Pharmaceuticals to serve as Managing Director Europe at Oberland Capital, a life science focused investment firm based in […]
Agreement - April 1, 2014
Index Pharmaceuticals signs deal with Almirall
The two companies have entered into a license agreement for European rights of the phase III drug candidate Kappaproct.
